New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
A new study links a variant of the apolipoprotein E gene called APOE ε4 to better memory in older age, even in the presence of amyloid plaques—a possible explanation for the variant’s persistence despite its association with an increased risk of Alzheimer’s disease.
A hormone treatment contaminated with amyloid-β given to mice caused the protein’s accumulation in their brains, suggesting the same could have occurred in humans given the therapy.
Aggregate-forming amyloid β proteins are replenished more slowly with age, and this may contribute to a person's risk of developing Alzheimer’s disease.
Blocking activity of a kinase in a mouse model protects Golgi in cells and reduces the build-up of amyloid β, a primary component of Alzheimer’s disease.
Antidepressant could prevent Alzheimer’s plaques; 12,000-year-old human skeleton sequenced; disentangling the mystery of octopus arms; taking a look at the ocular microbiome